In the latest session, PTC Therapeutics Inc. (NASDAQ: PTCT) closed at $47.28 down -0.08% from its previous closing price of $47.32. In other words, the price has decreased by -$0.04 from its previous closing price. On the day, 795622 shares were traded. PTCT stock price reached its highest trading level at $48.08 during the session, while it also had its lowest trading level at $46.44.
For a deeper understanding of PTC Therapeutics Inc.’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.20 and its Current Ratio is at 1.20.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Goldman on December 14, 2022, initiated with a Sell rating and assigned the stock a target price of $35.
On September 12, 2022, Jefferies started tracking the stock assigning a Buy rating and target price of $62.
On September 09, 2022, Morgan Stanley started tracking the stock assigning a Equal-Weight rating and target price of $54.Morgan Stanley initiated its Equal-Weight rating on September 09, 2022, with a $54 target price.
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jan 11 when Hill Emily Luisa sold 418 shares for $44.36 per share. The transaction valued at 18,542 led to the insider holds 47,086 shares of the business.
Peltz Stuart Walter sold 492 shares of PTCT for $21,825 on Jan 11. The CHIEF EXECUTIVE OFFICER now owns 55,488 shares after completing the transaction at $44.36 per share. On Jan 11, another insider, Peltz Stuart Walter, who serves as the CHIEF EXECUTIVE OFFICER of the company, sold 1,189 shares for $44.36 each. As a result, the insider received 52,744 and left with 169,282 shares of the company.
For the stock, the TTM Price-to-Sale (P/S) ratio is 4.75.
Stock Price History:
Over the past 52 weeks, PTCT has reached a high of $55.58, while it has fallen to a 52-week low of $25.01. The 50-Day Moving Average of the stock is 40.35, while the 200-Day Moving Average is calculated to be 42.10.
For the past three months, PTCT has traded an average of 684.84K shares per day and 1.06M over the past ten days. A total of 71.66M shares are outstanding, with a floating share count of 70.11M. Shares short for PTCT as of Oct 13, 2022 were 4.72M with a Short Ratio of 5.18M, compared to 5.45M on Sep 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 6.60% and a Short% of Float of 9.21%.
There are 14 different market analysts currently analyzing its stock. On average, analysts expect EPS of -$1.06 for the current quarter, with a high estimate of $0.27 and a low estimate of -$1.88, while EPS last year was -$2.03. The consensus estimate for the next quarter is -$1.31, with high estimates of -$0.82 and low estimates of -$1.69.
Analysts are recommending an EPS of between -$4.84 and -$7.44 for the fiscal current year, implying an average EPS of -$6.01. EPS for the following year is -$3.7, with 14 analysts recommending between -$1.04 and -$6.66.
A total of 11 analysts believe the company’s revenue will be $213.55M this quarter.It ranges from a high estimate of $236.14M to a low estimate of $181.67M. As of the current estimate, PTC Therapeutics Inc.’s year-ago sales were $165.23M, an estimated increase of 29.20% from the year-ago figure. For the next quarter, 4 analysts are estimating revenue of $202.61M, an increase of 36.20% over than the figure of $29.20% in the same quarter last year. There is a high estimate of $285.75M for the next quarter, whereas the lowest estimate is $169.5M.
A total of 14 analysts have provided revenue estimates for PTCT’s current fiscal year. The highest revenue estimate was $813.35M, while the lowest revenue estimate was $690M, resulting in an average revenue estimate of $723.9M. In the same quarter a year ago, actual revenue was $538.59M, up 34.40% from the average estimate. Based on 14 analysts’ estimates, the company’s revenue will be $878.4M in the next fiscal year. The high estimate is $1.12B and the low estimate is $725.1M. The average revenue growth estimate for next year is up 21.30% from the average revenue estimate for this year.